Drug Profile
Anti-ICAM-1 monoclonal antibody
Alternative Names: Anti-CD54 monoclonal antibody; Anti-ICAM-1Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Monoclonal antibodies
- Mechanism of Action Immunosuppressants; Intercellular adhesion molecule 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Diabetes mellitus; Rheumatoid arthritis; Transplant rejection
Most Recent Events
- 14 Jun 2001 No-Development-Reported for Transplant rejection in Germany (Unknown route)
- 14 Jun 2001 No-Development-Reported for Transplant rejection in Japan (Unknown route)
- 15 Apr 1997 No-Development-Reported for Diabetes mellitus in Japan (Unknown route)